Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Young

Internal Medicine Midlothian, VA Medical Doctor

NPI 1609849637 CMS profile 26971

348 Brown's Hill Ct, Midlothian, VA 23114

Open in the dashboard

General payments

$7,182

439 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Young of Midlothian, VA is reported in the CMS Open Payments database as having received $7,182 across 439 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,323 69
2024 General $1,194 64
2023 General $861 55
2022 General $775 52
2021 General $365 20
2020 General $610 40
2019 General $2,055 139

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Young
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Stephen Young were reported at $1,323. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Stephen Young Internal Medicine median Middle half National median
2019 $2,055 $159 $48–$570 $163
2020 $610 $119 $33–$402 $114
2021 $365 $135 $37–$521 $132
2022 $775 $141 $42–$496 $149
2023 $861 $149 $45–$519 $160
2024 $1,194 $154 $47–$537 $164
2025 $1,323 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,652 127 payments
  2. Lilly USA, LLC $637 38 payments
  3. Amgen Inc. $510 32 payments
  4. Sanofi-Aventis U.S. LLC $471 24 payments
  5. Abbott Laboratories $431 25 payments
  6. AstraZeneca Pharmaceuticals LP $361 25 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $269 16 payments
  8. Insulet Corporation $267 5 payments
  9. AbbVie, Inc. $245 17 payments
  10. Novartis Pharmaceuticals Corporation $231 10 payments
  11. Other $2,110 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,166 438 payments
  2. Education $16 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $1,359 106 payments
  2. RYBELSUS $991 77 payments
  3. FARXIGA $297 21 payments
  4. EVENITY $296 20 payments
  5. JARDIANCE $266 15 payments
  6. Omnipod $252 4 payments
  7. Prolia $243 15 payments
  8. FreeStyle Libre 3 $207 10 payments
  9. LEQVIO $192 8 payments
  10. MOUNJARO $182 12 payments
  11. Other $5,135 305 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 165 drugs

Part D claims

12,989

Median for Internal Medicine: 777

Drug cost

$1,875,587

Median for Internal Medicine: $73,373

Branded share of claims

24.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 255 $411,988
Jardiance Empagliflozin Brand 242 $297,434
Farxiga Dapagliflozin Propanediol Brand 97 $114,235
Mounjaro Tirzepatide Brand 50 $91,584
Januvia Sitagliptin Phosphate Brand 56 $79,366
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 63 $71,764
Trulicity Dulaglutide Brand 36 $65,759
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 54 $59,852
Eliquis Apixaban Brand 62 $51,586
Tresiba Flextouch U-100 Insulin Degludec Brand 29 $49,787

The 10 drugs with the highest cost, of 165 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$316,234

Of which drugs: $542

Medicare patients

740

Average age 76

Services billed

4,606

363 women, 377 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 40%
Ischemic heart disease 29%
Chronic kidney disease 27%
Depression 25%
Cancer 19%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 15 15 $542

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $147
$147 255 —
RYBELSUS
  • Novo Nordisk Inc $128
$128 — —
JARDIANCE
  • Lilly USA, LLC $77
  • Boehringer Ingelheim Pharmaceuticals, Inc. $34
$111 242 —
MOUNJARO
  • Lilly USA, LLC $74
$74 50 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

439 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record